Trial · NCT04706429
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
NCT04706429, Phase 2, Completed, Manchester University NHS Foundation Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy. Trials, record NCT04706429. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04706429
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
- NCT number
- NCT04706429
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 154 participants, actual
- Lead sponsor
- Manchester University NHS Foundation Trust
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Trientine, Placebo
- First posted
- 2021-01-12
- Last updated
- 2025-09-29
- Other registries' IDs
- eudract:2020-002242-17, isrctn:ISRCTN57145331
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Left ventricular mass indexed to body surface area (LVMi) | 12 months | Change in LVMi (g/m2), measured using CMR, from baseline to week 52. |
| Secondary | Urine copper excretion | 12 months | Cumulative urine copper excretion, measured using urinary copper, assessed from baseline to weeks 13, 26, 39 and 52. |
| Secondary | Exercise capacity | 12 months | Change in exercise capacity, measured using cardiopulmonary exercise testing (CPET), assessed from baseline to week 52. |
| Secondary | Number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia | 12 months | Change in number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia, in 24 hours, measured using ambulatory heart monitoring, assessed from baseline to week 52. |
| Secondary | Circulating high sensitivity troponin | 12 months | Change in circulating high sensitivity troponin, assessed from baseline to week 52. |
| Secondary | LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) | 12 months | Change in LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) measured using CMR, assessed from baseline to week 52. |
| Secondary | Peak left ventricular outflow | 12 months | Change in peak left ventricular outflow tract gradient, measured using CMR, assessed from baseline to week 52. |
| Secondary | Atrial volume and function | 12 months | Change in atrial volume and function, measured using CMR, assessed from baseline to week 52. |
| Other | LV myocardial cellular mass | 12 months | Change in LV myocardial cellular mass, measured using CMR, from baseline to week 52. |
| Other | LV myocardial extracellular mass | 12 months | Change in LV myocardial extracellular mass, measured using CMR, from baseline to week 52. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04706429
GET https://conductscience.org/api/trials/v1/NCT04706429/registered